Head-To-Head Review: Kaya (OTCMKTS:KAYS) & Aurinia Pharmaceuticals (NASDAQ:AUPH)

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Kaya (OTCMKTS:KAYS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Insider and Institutional Ownership

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 23.5% of Kaya shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Aurinia Pharmaceuticals and Kaya”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$175.51 million	6.53	-$78.02 million	($0.15)	-53.33
Kaya	$200,000.00	4.29	$1.61 million	($0.08)	-0.48

Kaya has lower revenue, but higher earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Kaya, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aurinia Pharmaceuticals and Kaya’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	-10.23%	-4.41%	-3.07%
Kaya	N/A	-9.79%	-1,143.19%

Volatility & Risk

Aurinia Pharmaceuticals has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, Kaya has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Aurinia Pharmaceuticals and Kaya, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0	1	3	0	2.75
Kaya	0	0	0	0	0.00

Aurinia Pharmaceuticals presently has a consensus price target of $10.00, indicating a potential upside of 25.00%. Given Aurinia Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Aurinia Pharmaceuticals is more favorable than Kaya.

Summary

Aurinia Pharmaceuticals beats Kaya on 9 of the 14 factors compared between the two stocks.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

About Kaya

Kaya Holdings, Inc., a vertically integrated legal cannabis enterprise, engages in the operation of psychedelic treatment clinics and medical cannabis dispensaries primarily in the United States. It offers a range of cannabis products, including flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. The company also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, it is involved in the development of a psychedelic treatment center under The Sacred Mushroom name, that provides its guests access to psilocybin treatments, located in Portland, Oregon. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. is headquartered in Fort Lauderdale, Florida.